Featured,Spotlight Stock Delic Labs Granted Permission to Study Psychedelics Compounds By Dennis Mutua April 18, 2022 Licensed cannabis and psilocybin research company focused on advanced research, testing and analysis for the psychedelic-wellness industry Delics Labs has been granted a section 56 exemption from Health Canada giving permission to...
Featured,Trends & Articles Cannsun Granted Regulatory Approval to Conduct Phase 2 Psilocybin Trials in Africa By Dennis Mutua April 15, 2022 Bio-pharmaceutical company focusing on developing and commercializing new medicines to optimize human health Cannsun Group PLC announced having been granted regulatory approval by the South African Health Products Regulatory Autho...
Featured,Spotlight Stock,Trends & Articles Numinus Inks Deal to Acquire Novamind in What Will Become Biggest Psychedelics Merger By Dennis Mutua April 13, 2022 Mental health and wellness company combining the practices of administering psychedelics medicine with holistic integrated psychotherapy Numinus Wellness Inc. (TSX: NUMI) (OTCMKTS: NUMIF) has signed a deal agreeing to acquire fell...
Featured,Trends & Articles Maryland Sends Bill to Fund Psychedelics Access by Veterans to Governor’s Desk By Dennis Mutua April 12, 2022 At the end of last week, legislators from Maryland send a bill which would create a state fund to fund cost-free access to psychedelics for military veterans suffering from brain injury and post-traumatic stress disorder (PTSD) to...
Featured,Spotlight Stock,Trends & Articles Recent Study Shows People Who Have Used Magic Mushrooms Are Less Likely to Develop Opioid Use Disorder By Dennis Mutua April 08, 2022 A recently conducted study by researchers from Harvard University people who have used psilocybin specifically magic mushrooms at some point in their lives are 30% less likely to suffer from opioid use disorder compared to those w...
Featured,Spotlight Stock,Trends & Articles Field Trip Receives US Patent for Novel Psychedelic Molecule FT-104 By Dennis Mutua April 06, 2022 Biotechnology company specializing on developing and delivering technology enabled psychedelic therapies Field Trip Health Ltd. (NASDAQ: FTRP) (TSX: FTRP) has been granted a patent for claims linked to FT-104, the company’s firs...
Featured,Spotlight Stock Health Canada Approves First Special Access Program Requests for Psilocybin By Dennis Mutua April 05, 2022 About two weeks ago, Dr. Valorie Masuda MD received approval from the Special Access Program (SAP) to treat six patients suffering from end-of-life distress with psilocybin and psychotherapy. In support of the SAP application, Psy...
Featured,Shroom News Georgia Legislators Pass Bill to Form Psychedelic Study Committee By Dennis Mutua March 30, 2022 Lawmakers from Georgia have passed a bill advocating for the creation of a psychedelic study committee which will be dedicated in investigating the therapeutic potential of psychedelics like psilocybin, MDMA, DMT among others. The...